CMS Off-Label Cancer Drug Policy Will Have “Very Narrow” Focus
Executive Summary
The Centers for Medicare & Medicaid Services' pending policy decision on coverage of off-label cancer drugs will have a "very narrow" focus, Coverage & Analysis Group Director Steve Phurrough, MD, told the Schwab Soundview Washington Research Group health care conference May 6